A review of the safety of vaccines used in routine immunization in Africa.

BACKGROUND: Despite the significant role played by vaccines in global health, concerns over vaccine safety have increased tremendously over the years. There have been occasions where vaccines have caused rare, adverse reactions some of which have led to hospitalizations and even death. It is therefore important to establish the safety profile of routinely used vaccines in order to allay fears pertaining to their use.
OBJECTIVES: This review was aimed at pooling together the safety data of selected vaccines used for routine immunization in Africa, a region of the world with paucity of vaccine safety data.
METHODS: Adverse Events Following Immunization safety data was searched for rotavirus, yellow fever, measles, rubella, tuberculosis (Bacillus Calmette Guerin-BCG), pneumococcal, Haemophilus Influenza type b, polio, meningococcal and the influenza A (H1N1) vaccines in PUBMED, Google Scholar, Clinical trials.gov and Cochrane controlled register of trials databases.
RESULTS: A total of twenty-four serious AEFIs and twenty-three minor AEFIs were identified from the review. The strength of association between AEFIs and vaccine was high for tuberculosis vaccine and moderate for all other vaccines.
CONCLUSION: Even though AEFIs (including mild and severe) were identified in the review, all the vaccines studied were generally well tolerated.

Introduction

Vaccines are amongst the top life-saving interventions developed in the history of mankind preventing millions of diseases and deaths annually1. The elimination of the deadly diseases, smallpox and rinderpest for instance became possible because of the development and usage of their respective vaccines on a large scale across the globe2–4.

Despite the significant role vaccines play in global health, concerns over their safety have increased tremendously over the years5. It is important for the general population to be assured that vaccines are less likely to cause fatalities than the infectious diseases they are meant to prevent and thus generally safe for use. This notwithstanding, there have been occasions where vaccines have caused rare, adverse reactions some of which have led to hospitalizations and even death6. This has caused a section of the public to believe that vaccines are harmful, posing a threat to global health as it is a major cause of low turnout in mass vaccination campaigns. During the United States of America multi-state measles outbreak of 2014–2015 for instance, several infected persons were not vaccinated against measles or had unknown vaccination status because of false alarms about fatalities caused by measles containing vaccines which they had read from various websites and print media7–9. These fears need to be allayed through educating and adequately communicating the safety profile of vaccines- a very important aspect of vaccine pharmacovigilance. As infectious diseases such as Ebola virus disease continue to emerge and populations continue to increase particularly in poor regions like Africa, the use of vaccines will increase proportionally and hence the need to intensify measures to ensure their safety10. This calls for commitment towards ensuring good vaccine pharmacovigilance practices by all stakeholders including but not limited to medicine regulators, vaccine marketing authorization holders, healthcare professionals, policy makers, public health practitioners and academic researchers. Vaccine pharmacovigilance has been defined as the science and activities relating to the detection, assessment, understanding and communication of adverse events following immunization (AEFI) and other vaccine and immunization related issues and the prevention of the untoward effects of the vaccine or immunization11. One way of improving vaccine safety is the identification and prompt reporting of the adverse events associated with their use to regulatory bodies as the pattern of AEFIs of a particular vaccine product helps to trace the possible cause of the AEFI.

The WHO/CIOMS classify AEFIs under 5 possible causes and these include vaccine product related reactions (e.g. extensive limb swelling following DTP vaccination), vaccine quality related reactions (e.g. failure of the manufacturer to completely inactivate a virus used in the vaccine manufacture), immunization error related reactions (e.g. transmission of infection by contaminated multi-dose vial), immunization anxiety related reactions (e.g. vasovagal syncope) and coincidental events (e.g. fever after vaccination resulting from a co-existing infection like malaria)12,13. AEFIs are classified as serious if they lead to death, hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, congenital anomaly or life threatening event12. Minor vaccine reactions usually occur within a few hours of injection and resolve after a short period of time posing little or no danger. These may include pain, swelling and redness at the site of injection whereas minor systemic reactions may include fever, malaise, muscle pain, headache and loss of appetite12. It is important to carry out causality assessment of rare but serious AEFIs with a vaccine product because most AEFIs are coincidental events that are falsely attributed to vaccines due to possible temporal associations14. Temporal association reports could help future researchers to conduct studies such as controlled clinical trials to generate supportive data for a causal hypothesis15. An AEFI investigation may lead to the temporal suspension of a vaccination exercise pending investigation outcome. An AEFI investigation outcome could either recommend the continuation of the vaccination exercise or the outright suspension of vaccination exercise. Vaccine manufacturers must always assess all batches of vaccnes to ensure that good manufacturing practice principles have been duly followed. Most AEFIs resulting from bad manufacturing practices have largely occurred during the introduction of new vaccines for outbreaks which need quick interventions to avoid the rapid spread of disease. Examples of such AEFIs include Bell's palsy resulting from the inactivated nasal flu vaccine and intussusception from the rotavirus vaccine, Rotashield16,17. To avoid these AEFIs or reduce their prevalence to the barest minimum, vaccines need to be rigorously monitored for AEFIs especially when they are newly introduced, despite their potential for infection prevention.

Immunization errors, such as the wrong medicine and the wrong route of administration by healthcare professionals have also contributed to AEFIs. A classic example is the wrongful administration of insulin instead of diphtheria, pertussis and tetanus (DTP) vaccine to 70 infants resulting in 21 deaths18.

Africa is amongst the poorest regions of the world where large doses of vaccines are administered due to the high burden of infectious diseases which require vaccination as a preventive measure. Evidence in the literature suggests that aside from mass vaccination campaigns, there are many late stage vaccine clinical trials being conducted in Africa19,20. However, there is paucity of synthesized body of evidence on the safety of the vaccines used in routine and mass vaccination programs in Africa. Safety data from vaccination campaigns and clinical trials are a good source of information for synthesizing a body of evidence on vaccine safety. This review therefore aimed at pooling together the safety data of selected vaccines used for routine vaccinations using mass vaccination and vaccine clinical trial studies conducted in Africa. In achieving this aim, the types of AEFI identified in vaccine trials and mass vaccination campaigns and the strength of association between the AEFIs and the selected vaccines were assessed. The evidence generated from this study will serve as a baseline for future researchers in vaccine safety and stimulate other researchers to investigate the safety profile of other vaccines not studied in this review. It could also serve as a guide to vaccine pharmacovigilance experts and expanded program on immunization managers as to the likely AEFIs to expect during routine and mass vaccinations thereby contributing to improving vaccine safety in Africa.

Methods

Vaccine information source

The Centres for Disease Control and Prevention (CDC) website was searched for approved common vaccines for routine immunization in the United States of America and other regions of the world. Out of the twenty-six approved vaccines on the CDC website, seventeen were routinely used in vaccinations in Africa21. An initial literature search revealed that nine out of these seventeen vaccines were extensively used in Africa. These included rotavirus, yellow fever, pneumococcal, measles, rubella, tuberculosis (BCG), Haemophilus Influenza type b (Hib), polio and meningococcal vaccines. Further literature search showed that the influenza A (H1N1) vaccine has also been used in many countries in Africa even though not published on the CDC website and was therefore added to the nine.

Eligibility criteria

Inclusion/exclusion criteria

The studies included in the database search were phase 1 clinical trials, phase 2 and 3 controlled clinical trials and studies on mass vaccination campaigns conducted in Africa. Information on vaccine AEFIs from grey literature was excluded. The types of mass vaccination campaign study designs searched for in the databases included prospective, cohort and case-control. Studies reporting adverse events following immunizations via both active and passive surveillance on the ten selected vaccines either as single ingredient vaccines or in combination of two or more were included. Studies which met the inclusion criteria but failed to mention the types of AEFIs observed were excluded. Multi-centre studies which included both African and non-African countries were excluded. All studies used were ensured to have been published in the English language. Two experienced researchers in systematic review methodology independently reviewed the titles and abstracts identified and reached a consensus on the inclusion and exclusion of studies.

Types of participants, interventions, comparisons and outcomes

The participants, interventions, comparisons and outcomes (PICO) framework was adopted in the design of the systematic review protocol and served as the guide for the selection of clinical trials for the review. The potential participants in the included studies were all likely persons in various vaccine target populations (i.e infants, adolescents, pregnant women, adults and the elderly). The interventions were vaccines used either on routine basis in infant immunization schedules or mass vaccination campaigns in the prevention of infectious diseases and these included the rotavirus, yellow fever, pneumococcal, measles, rubella, tuberculosis (BCG), Haemophilus Influenza type b (Hib), polio, meningococcal and influenza A (H1N1) vaccines. Regarding the comparators to the vaccines studied, studies making relevant comparisons of vaccines against a control, such as placebo, unexposed or untreated group, or alternate vaccine formulation were included. Acceptable outcome measures included intervention efficacy, effectiveness, or safety. The major outcome evaluated was safety of the vaccines to be studied. However, studies that did not evaluate vaccine safety as a primary outcome were included if AEFI data were reported for the vaccine target populations.

Assessment of methodological quality and strength of evidence

Studies meeting the inclusion criteria were independently verified for methodological quality using the following criteria: studies with clearly defined subjects, studies with clearly defined outcomes, studies with adequate sample size, studies with responses representative of the study population, studies with high response rate, studies using validated measures, studies with measures consistent with the set aims and objectives, studies with conclusions consistent with results, studies with clear methodology and studies with clear analysis. These criteria were obtained from the Critical Appraisal Skills Program (CASP) which has been used by several authors in systematic reviews due to its reliability22,23. The McHarm instrument was used to evaluate the quality of the studies with regard to their assessment of AEFIs24. Studies that reported time of AEFI onset, AEFI severity and defined AEFI using standard, precise definitions were rated higher than those that did not. The overall strength of evidence of the vaccine safety outcome was determined by the Agency for Healthcare Research and Quality (AHRQ) guidelines25. The AHRQ guidelines prescribe 4 strength of evidence levels namely high (high confidence in AEFI reflecting the true effect), moderate (moderate confidence in the observed AEFI; further studies may alter the AEFI outcome), low (low confidence in observed AEFI; further studies more likely to alter the AEFI outcome) and insufficient (unavailable evidence or no confidence in observed AEFI outcome).

Search strategy

The electronic databases searched included PUBMED, Google Scholar, Clinical trials.gov and Cochrane controlled register of trials. A three-step search strategy was utilized in the review. An initial search of PUBMED was undertaken to identify subject headings and potential keywords relevant to the systematic review. The subject headings and potential keywords in this initial search included “vaccine name” AND “clinical trials” AND “Africa” and “vaccine name”, “mass vaccination campaigns” AND “Africa” and “vaccine safety” AND “Africa”. A second search was carried out in Google Scholar, Clinical trials. gov and Cochrane controlled register of trials databases using these keywords, subject headings and index terms. The third search involved a hand search of the reference lists of the identified articles for additional studies that may have been missed during the systematic search. The reference lists selected for full text review were searched for the relevance of the articles. The search considered articles published from 1st January 2000 to 31st December 2015 only. Literature search was done on the 27th of May 2016 using the proposed structure according to the preferred reporting items for systematic reviews and meta-analyses26.

Screening and data extraction

The initial screening of published papers was conducted by one reviewer; a two reviewer system was employed throughout the rest of the review workflow. Search results were imported into Mendeley referencing software and one reviewer screened titles and abstracts of the published papers. Articles and titles with no bearing to the review were discarded. Consensus and discussion with a second reviewer was the means of resolving uncertainty during the screening process regarding inclusion and exclusion of studies. A data extraction sheet was used to collect relevant information from the included studies (Appendix 1). This information included the details of the author, the aims and objectives of the study, the research setting, the research participants and sample size, the study design used and vaccine safety related information reported in the studies. Common Terminology Criteria for Adverse Events classification system (Appendix 2) was used to characterize the severity of AEFIs reported in the studies27. Tables were used to present the summary of extracted data.

Quality analysis (meta-analysis) of included studies

Data analysis was planned to provide a detailed overview of the heterogeneity among AEFI definitions and reporting patterns in the included studies based on the WHO /CIOMS definitions. The analysis performed after ensuring homogeneity of studies included:

Assessment of whether AEFIs are defined or reported in the included studies.

Assessment of studies that reported AEFI severity and defined AEFI using standard and precise definitions

Characterization of consistency in AEFI names and definitions.

Ranking of reported AEFIs into minor and serious based on WHO/CIOMS definitions.

Assessing the strength of evidence of AEFI outcomes

Results

Results of literature search

After the literature search, 3,989 studies were identified and recorded. The electronic databases (PUBMED, Google Scholar, Clinical trials.gov and Cochrane controlled register of trials) search retrieved 3,932 studies whereas 57 were obtained from the reference list of the included studies. Out of these articles, 3,840 duplicates were identified and removed, leaving 149 studies to be assessed. The titles and abstracts of the remaining studies were closely reviewed against the inclusion and exclusion criteria and 101 studies were excluded. An additional 36 were excluded after scrutinizing the text against the inclusion and exclusion criteria. The entire process led to 12 good quality studies that met the inclusion criteria as presented in the PRISMA flow diagram in Fig 1 which is based on the Moher et al, 2009 study27.

Fig 1

PRISMA diagram for the review

Characteristics of included studies

There was one study on Haemophilus influenza type b vaccine28, two studies on influenza A (H1N1) vaccine29,30, one study on measles-rubella vaccine31, one study on meningococcal vaccine32, one study on oral polio vaccine33, two studies on pneumococcal vaccine34,35, one study on rotavirus vaccine36, two BCG vaccine studies37,38 and one yellow fever vaccine study39. With the exception of only one study which assessed two vaccines (Measles-Rubella) in one formulation31, all the remaining studies assessed vaccines containing only one active ingredient. Vaccinees in the included studies were neonates, infants, children, adolescents and adults. All studies included in this review were published between 2001 and 2013 and were clinical trials, prospective and cohort studies. No case-control study was retrieved from the literature search. The study with the least number of participants was the phase 1 study in South Africa in which 24 healthvolunteers were recruited37.

Another characteristic of the studies used in the review was that participants from all parts of Africa i.e. West, East, Central, North and Southern Africa were represented. The West African countries were Ghana29,36, Togo39, Benin39, Mali32,36,39, Senegal32,39, Liberia39, Guinea39, Sierra Leone39 and Gambia32,34. The east African country was Kenya39. The central African countries were Cameroon39 and Democratic Republic of Congo33. The North African countries were Egypt31 and Tunisia30 whereas South Africa was the only Southern African country28,35,37,38. Three of the studies32,36,39 were multi-centre in design whereas the remaining nine were conducted in only one country. Further details of the location, study objective, participant characteristics, study design and AEFI outcome are presented in Table 1.

Table 1

Location, study objective, participant characteristics, study design and AEFI outcome of studies

Location	Objective	Participants	Study design	AEFI outcome
Korle-Bu Teaching Hospital (KBTH), Ghana29	To determine the distribution and types of AEFI after A(H1N1) 2009 vaccination	5,870 healthcare workers aged 18 years and over at KBTH	Prospective study	Minor AEFIs: Headaches, dizziness, fatigue, muscle and joint aches, weakness, fever, injection-site pain, tachycardia, tinnitus and decreased appetite some of which worsened and led to hospitalization after 24hours
Rural areas of Ghana and Kenya and an urban area of Mali36	To assess the efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis	5,468 infants aged 4 to 12 weeks without symptoms of gastrointestinal disorders	Randomized multi-centre, doubleblind, placebo-controlled trial	Serious AEFIs: gastroenteritis (watery diarrhoea, vomiting, fever and dehydration) which occurred more in placebo group than study group
Benin, Cameroon, Guinea, Liberia, Mali, Senegal, Sierra Leone, and Togo39	To assess the adverse events following yellow fever preventive vaccination	38 million people in the general population of these eight countries	Data collected during this vaccination campaigns from 2007 to 2010 in the eight countries	Serious AEFIs: hypersensitivity reactions, suspected Yellow Fever Vaccine Associated Neurological Disease (YFVAND) and Yellow Fever Vaccine Associated Viscerotropic Disease (YFVAVD)
Tunisian population30	To evaluate the effectiveness and the safety of the two H1N1 vaccines available in Tunisia: Focetria(®) and Panenza(®	601 vaccinated subjects	Prospective study Safety assessed by occurrence of unexpected AEFIs	Common/mild AEFIs disappearing after a few days. Focetria(®) associated with more AEFIs than Panenza(®)
Eastern Gambia34	To assess the efficacy of a nine-valent pneumococcal conjugate vaccine	17,437 children aged 6–51 weeks	Randomised, placebo-controlled, double-blind trial.	Few serious AEFIs occurring more in the placebo group than study group. Major serious AEFI: Radiological pneumonia
Nation-wide measles–rubella immunization campaign in Egypt31	To assess the progress towards measles and rubella elimination	95% of the children, adolescents, and young adults 2–20 years old	Campaign was conducted in 2 phases from 2008 to 2009.	Minor AEFIs: Few mild AEFIs and brief fainting. Serious AEFIs: Stevens-Johnson Syndrome, anaphylaxis, seizure and encephalitis
Worcester, located 110 km from Cape Town, South Africa37	To assess the safety and immunogenicity of a new Tuberculosis Vaccine, MVA85A	24 healthy volunteers aged 18 to 50 years	Open-label phase 1 safety and immunogenicity study. -Participants monitored over a period of 12 months for AEFIs	Minor AEFIs: swelling, pruritus and pain; systemic reactions were feeling unwell, tiredness, fever, athralgia, headache, myalgia and nausea Major AEFI: Hysterectomy
Durban functional region and surrounding regions, South Africa38	Safety of intradermal Copenhagen BCG vaccine evaluation	9,763 neonates	Prospective study carried out between July 1997 and June 1999 AEFI evaluated 6 weeks after immunization	Minor AEFIs: Extranodal injection site abscesses, lymphadenopathy, swelling, Serious AEFIs: erythema, keloid formation and skin ulcers.
Soweto, South Africa35	Efficacy of a 9-valent pneumococcal conjugate vaccine evaluation	39,836 children at age 6, 10 and 14 weeks	Randomized, double-blind, place-bocontrolled trial	Serious AEFIs: viral pneumonia, generalized seizures, unspecified seizures, hyperactive airway disease and asthma higher in the study group than placebo group
Three Clinics in Pretoria, South Africa28	To assess the safety and immunogenicity of two Haemophilus influenzae type b conjugate vaccines (Vaxem Hib versus Hib TITER)	331 babies at age 6, 10 and 14 weeks	Phase 2, observer-blind, multicentre, randomised, controlled, non-inferiority study	Minor AEFIs: Injection site redness, swelling and fever
Kinshasa, Democratic Republic of Congo (DR Congo)33.	To investigate the nature and frequency of AEFI associated with oral polio vaccines (OPV)	Over 9 million pupils and university students	Prospective study in which patient individual case safety report was used as a questionnaire to study AEFIs	Minor AEFIs: headache, abdominal pain, fever, diarrhoea and asthenia -Serious but rare AEFIs: paralysis and asthma-like reactions
Mali, Gambia and Senegal32	To evaluate the immunogenicity and safety of a single injection of PsA-TT (Meningococcal A) conjugate vaccine	601 children 12 to 23 months of age (Group A) and 900 subjects between 2 and 29 years of age (Group B)	Multicentre, double-blind, randomized, controlled, comparative trial	Minor AEFIs: Tenderness and induration at injection site, headache, fever, vomiting and diarrhoea. Serious AEFIs: Bronchopneumonia, protein energy malnutrition, gastroenteritis, marasmus, cerebral malaria, road traffic accident leading to haemorrhage and internal injuries, meningococcal A meningitis and death.

Meta-Analysis (Strength of evidence of AEFI outcomes)

The strength of AEFI outcomes based on AHRQ guidelines and reasons are summarized in Table 2.

Table 2

Summary of vaccine safety related outcomes and strength of evidence

Vaccine	Strength of evidence of AEFI	Reason
Haemophilus Influenza type b	Moderate	Only one study reporting AEFIs was identified28.
Influenza A (H1N1)	Moderate	Two studies were identified but only one study29. mentioned the specific AEFIs. The specific AEFIs were not mentioned in the other study30.
Measles-Rubella	Moderate	High confidence in AEFI outcome because of high sample size but only one study reported these AEFIs31.
Meningococcal	Moderate	High confidence in AEFI outcome because of long term follow-up of study participants. However, only one study reported these outcomes making strength of evidence moderate32. Further studies are needed for comparison of AEFI outcomes with that in current study.
Oral Polio	Moderate	High confidence in AEFI outcome because of high sample size but only one study was identified reporting these AEFIs33. Further studies are needed for comparison of AEFI outcomes with that in current study.
Pneumococcal	Moderate	Two studies identified34, 35 but only few minor AEFIs occurred in both studies. Further studies are needed for clarity.
Rotavirus	Moderate	Only one study identified with AEFIs. There is the need for further studies for AEFI comparison36.
Tuberculosis (BCG)	High	Two studies identified with similar AEFIs37, 38.
Yellow fever	Moderate	Only one study identified with the AEFIs observed39. More studies are needed for clarity

Discussion

Twenty four serious AEFIs were identified in this review and included Stevens-Johnson Syndrome, anaphylaxis, seizure, encephalitis, bronchopneumonia, protein energy malnutrition, gastroenteritis, marasmus, cerebral malaria, road traffic accident leading to haemorrhage and internal injuries, meningococcal A meningitis, paralysis, asthma and asthma-like reactions, radiological pneumonia, viral pneumonia, generalized seizures, unspecified seizures, hyperactive airway disease, elective hysterectomy, hypersensitivity reactions, suspected yellow fever vaccine associated neurological disease (YFVAND), suspected yellow fever vaccine associated viscerotropic disease (YFVAVD), hospitalization and death. The serious AEFIs associated with deaths were linked to the meningococcal vaccine. Studies from other regions of the world recorded no fatal AEFIs association with the meningococcal vaccine as recorded in this review indicating that further research on the meningococcal vaccine may be needed to confirm the findings in this study. With the exception of the Hib ad H1N1 vaccine, all other vaccines were associated with serious AEFIs. The finding with the H1N1 vaccine is consistent with findings from other studies which found no serious AEFI following its administration confirming its safety40,41.

Active forms of organisms used in vaccine manufacture could cause serious AEFIs. For instance OPV and pneumococcal vaccine were associated with paralysis and radiological pneumonia respectively. Even though, the inactivated polio vaccine (IPV) which is being used in many developed countries is associated with paralytic poliomyelitis to a far lesser extent42, it is also associated with allergic reactions such as food allergy and the asthma-like reactions identified in this review43. However, because the OPV associated paralysis and asthma-like reactions were rare, the use of the OPV may be continued in routine immunization. However, further comparative studies of OPV and IPV in African settings will be beneficial in informing policy as to whether to switch to the IPV or not.

Rotavirus vaccine was associated with serious gastroenteritis. A systematic review on the safety of routinely used vaccines conducted in the United States of America (USA) found that rotavirus vaccine was not associated with gastroenteritis but rather, cough, runny nose and irritability.44 Moreover, a study conducted in Australia also observed intussusception in children aged 1 to 21 days after immunization with RotaTek(®, a popular brand of rotavirus vaccine) and this was consistent with the finding in a study in Mexico after immunization with another brand, Rotarix(®45. These findings are related to concerns which led to the withdrawal of the rotavirus vaccine, Rotashield(® from the USA market demonstrating the need to study the safety of the rotavirus vaccine extensively46. The serious AEFIs in the yellow fever multi-centre study, yellow fever vaccine associated neurological disease (YFVAND) and suspected yellow fever vaccine associated viscerotropic disease (YFVAVD) have been observed in other studies and must be noted carefully by vaccine program managers and Expanded Program on Immunization managers47,48. Due to these serious AEFIs, Lindsey et al., 2008 in their study concluded that yellow fever vaccination should be limited to persons travelling to areas where the risk of yellow fever is expected to exceed the risk of serious adverse events after vaccination, or if not medically contraindicated, where national regulations require proof of vaccination to prevent introduction of yellow fever48.

Minor AEFIs are usually local reactions at the site of injection and others that resolve within a few days after immunization posing little or no danger to the vaccinee. Twenty-three minor AEFIs were identified in the review and included headaches, dizziness, muscle and joint aches, weakness, fever, injection-site pain, diarrhoea, redness, tenderness and induration of site of injection, swelling, abscesses, brief fainting, abdominal pain, tachycardia, tinnitus, decreased appetite, asthenia, diarrhoea, pruritus, erythema, lymphadenopathy, keloid formation and ulcers of the skin. Besides the active ingredients used in the preparation of vaccines, certain additives are also included to increase their potency and preserve them. These include but not limited to suspending agents (e.g. water and saline), preservatives (e.g. thimerosal), stabilizers (e.g. sorbitol and hydrolyzed gelatin), adjuvants (mainly aluminum salts), residuals in the growth medium and antibiotics (e.g. neomycin and streptomycin).49 Certain individuals may react to the active vaccine products or these additives leading to AEFIs. It is therefore imperative to document any such previous reactions to prevent their re-occurrence in future.

It is important to note that AEFIs are not necessarily caused by vaccine products but several other factors necessitating the need for associations and causality assessments on AEFIs12,13,50 in order to make an informed decision as to whether to withdraw a vaccine or not. In this review, the strength of association between AEFIs and vaccine was high for Tuberculosis vaccine and moderate for all other vaccines.

Study limitations

The major limitation of this study was the inclusion of studies in which AEFIs were reported passively due to scanty data on active AEFI reporting studies. Even though passive AEFI are useful, they can sometimes be subjective and unreliable. Moreover, participants in the included studies were not followed up over a long period of time to adequately identify rare and late occurring AEFIs. Although clinical trials are rigorous in nature, they also do not have large sample sizes to adequately identify rare AEFIs. It will therefore be more appropriate to use pharmacoepidemiological study designs such as cohort event monitoring in which participants are monitored over a long period of time with active reporting mechanisms to establish better associations between vaccines and AEFIs.

Conclusion

Overall, all the vaccines studied were generally well tolerated. The strength of association between AEFIs and vaccine was high for tuberculosis (BCG) vaccine and moderate for all other vaccines.